EUVIMEDEUVIMED entdecken
Crossref

Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data

Koichi Uemura iD, Hiroki Ito, Ryosuke Jikuya, Takuya Kondo, Tomoyuki Tatenuma iD, Takashi Kawahara iD, Yusuke Ito, Mitsuru Komeya, Kentaro Muraoka iD, Hisashi Hasumi, Hiroji Uemura, Kazuhide Makiyama iD

International Journal of Urology · 2024

DOI: 10.1111/iju.15437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Koichi Uemura und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yokohama City University Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In December 2021, enfortumab vedotin (EV), an antibody‐drug conjugate directed against nectin‐4, was approved in Japan as a new treatment after platinum‐containing chemotherapy and PD‐1/PD‐L1 inhibitors. This study evaluated, using real‐world data, the efficacy and safety of EV therapy in patients with metastatic urothelial carcinoma (mUC). Materials and methods Fifty‐five patients with mUC who discontinued pembrolizumab therapy due to disease progression between June 2018 and April 2023 at Yokohama City University Hospital were evaluated retrospectively. Of the 55 patients, 25 received EV therapy (EV group) and 30 did not (non‐EV group). All patients who underwent EV therapy were diagnosed with disease progression after the approval of EV in Japan.

Results

The median (range) follow‐up period after pembrolizumab discontinuation was 6.3 (0.7–31.1) months. There were eight (32.0%) deaths due to cancer in the EV group and 27 (90.0%) in the non‐EV group. The overall survival (OS) after pembrolizumab discontinuation was not reached in the EV group versus 2.6 months in the non‐EV group ( p < 0.001). A multivariate analysis revealed that EV therapy (EV vs. non‐EV group; hazard ratio 0.26; 95% confidence interval 0.16–0.41; p < 0.001) was an independent prognostic factor for OS.

Conclusion

EV prolonged OS in mUC following pembrolizumab therapy in real‐world data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Transitional CellAntineoplastic Agents, ImmunologicalHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overJapanUrinary Bladder NeoplasmsAntibodies, MonoclonalUrologic NeoplasmsDisease ProgressionSurvival RateImmunoconjugates

Stichwörter der Autor:innen

enfortumab vedotinmetastatic urothelial carcinomamultivariable analysis

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumabenfortumab vedotinAntineoplastic Agents, ImmunologicalAntibodies, MonoclonalImmunoconjugates

Autor:innen und Institutionen

  • Department of Urology, Yokohama City University Hospital, Kanagawa, Japan.
  • Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan.

ORCID-Profile: Koichi Uemura, Tomoyuki Tatenuma, Takashi Kawahara, Kentaro Muraoka, Kazuhide Makiyama

Zitieren

APA

Uemura, K., Ito, H., Jikuya, R., Kondo, T., Tatenuma, T., Kawahara, T., Ito, Y., Komeya, M., Muraoka, K., Hasumi, H., Uemura, H., & Makiyama, K. (2024). Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data. International Journal of Urology. https://doi.org/10.1111/iju.15437

Vancouver

Uemura K, Ito H, Jikuya R, Kondo T, Tatenuma T, Kawahara T, et al. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data. International Journal of Urology. 2024. doi:10.1111/iju.15437

BibTeX
@article{Uemura2024,
  author = {Uemura, Koichi and Ito, Hiroki and Jikuya, Ryosuke and Kondo, Takuya and Tatenuma, Tomoyuki and Kawahara, Takashi and Ito, Yusuke and Komeya, Mitsuru and Muraoka, Kentaro and Hasumi, Hisashi and Uemura, Hiroji and Makiyama, Kazuhide},
  title = {Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15437}
}
Kostenlos starten →